Hyloris Pharmaceuticals SA (EBR: HYL)
Belgium
· Delayed Price · Currency is EUR 5.30
-0.24 (-4.33%)
Dec 20, 2024, 5:35 PM CET
Hyloris Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Operating Revenue | 5.63 | 2.09 | 0.9 | 3.1 | 0.18 | 0.09 | Upgrade
|
| Other Revenue | 1.32 | 2.13 | 1.49 | - | - | - | Upgrade
|
| Revenue | 6.94 | 4.21 | 2.39 | 3.1 | 0.18 | 0.09 | Upgrade
|
| Revenue Growth (YoY) | 112.46% | 76.54% | -22.90% | 1669.14% | 92.31% | 0% | Upgrade
|
| Cost of Revenue | 0.16 | 0.09 | 0.09 | 0.11 | 0.15 | 0.07 | Upgrade
|
| Gross Profit | 6.79 | 4.12 | 2.29 | 2.99 | 0.03 | 0.03 | Upgrade
|
| Selling, General & Admin | 6.21 | 5.55 | 3.52 | 2.9 | 2.19 | 0.81 | Upgrade
|
| Research & Development | 13.95 | 14.42 | 10.27 | 5.03 | 2.93 | 1.37 | Upgrade
|
| Other Operating Expenses | 0.4 | - | 0.01 | 5.38 | -0.02 | -0.09 | Upgrade
|
| Operating Expenses | 20.55 | 19.97 | 13.8 | 13.31 | 5.11 | 2.1 | Upgrade
|
| Operating Income | -13.76 | -15.85 | -11.51 | -10.33 | -5.08 | -2.07 | Upgrade
|
| Interest Expense | -0.1 | -0.05 | -0.22 | -0.56 | -0.84 | -0.41 | Upgrade
|
| Interest & Investment Income | 0.93 | 0.87 | 0.07 | 0.03 | 0.01 | - | Upgrade
|
| Earnings From Equity Investments | -0.11 | -0.15 | -0.13 | -0.19 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.02 | 0.02 | 0.35 | -0.19 | 0.28 | -0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.22 | -0.22 | -0.23 | -0.03 | -1.57 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -13.24 | -15.38 | -11.68 | -11.26 | -7.2 | -2.58 | Upgrade
|
| Asset Writedown | - | - | - | -0.02 | -0.48 | -3.2 | Upgrade
|
| Other Unusual Items | - | - | -0.23 | - | 0.53 | - | Upgrade
|
| Pretax Income | -13.24 | -15.38 | -11.9 | -11.28 | -7.14 | -5.78 | Upgrade
|
| Income Tax Expense | - | - | 0 | 0.3 | 0 | -0.01 | Upgrade
|
| Earnings From Continuing Operations | -13.24 | -15.38 | -11.91 | -11.58 | -7.15 | -5.77 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | - | 0.4 | Upgrade
|
| Net Income | -13.24 | -15.38 | -11.91 | -11.58 | -7.15 | -5.37 | Upgrade
|
| Net Income to Common | -13.24 | -15.38 | -11.91 | -11.58 | -7.15 | -5.37 | Upgrade
|
| Shares Outstanding (Basic) | 28 | 28 | 27 | 26 | 22 | 14 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 28 | 27 | 26 | 22 | 14 | Upgrade
|
| Shares Change (YoY) | 1.44% | 2.95% | 5.29% | 18.40% | 51.63% | 6.43% | Upgrade
|
| EPS (Basic) | -0.47 | -0.55 | -0.44 | -0.45 | -0.33 | -0.37 | Upgrade
|
| EPS (Diluted) | -0.47 | -0.55 | -0.44 | -0.45 | -0.33 | -0.37 | Upgrade
|
| Free Cash Flow | -12.34 | -13.11 | -13.12 | -11.36 | -4.57 | -4.57 | Upgrade
|
| Free Cash Flow Per Share | -0.43 | -0.47 | -0.48 | -0.44 | -0.21 | -0.32 | Upgrade
|
| Gross Margin | 97.77% | 97.79% | 96.06% | 96.54% | 17.14% | 27.47% | Upgrade
|
| Operating Margin | -198.27% | -376.03% | -482.11% | -333.49% | -2900.57% | -2275.82% | Upgrade
|
| Profit Margin | -190.79% | -364.97% | -498.79% | -374.00% | -4082.86% | -5904.40% | Upgrade
|
| Free Cash Flow Margin | -177.71% | -311.01% | -549.69% | -366.83% | -2611.43% | -5021.98% | Upgrade
|
| EBITDA | -13.53 | -15.74 | -11.43 | -10.27 | -5.03 | -2.02 | Upgrade
|
| D&A For EBITDA | 0.24 | 0.11 | 0.08 | 0.05 | 0.05 | 0.05 | Upgrade
|
| EBIT | -13.76 | -15.85 | -11.51 | -10.33 | -5.08 | -2.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.